NEW YORK, June 8 — An experimental oral drug has nearly doubled survival in patients with advanced pancreatic cancer, offering rare hope against one of medicine’s deadliest diagnoses. The drug, daraxonrasib, targets multiple RAS mutations at once, making resistance harder, and has shown significant promise in a Phase 3 trial.
More than 90% of pancreatic cancers are driven by mutations in a gene called KRAS, which was long considered undruggable due to its surface offering no foothold. Daraxonrasib works by grabbing a helper molecule called cyclophilin A, forming a complex that clamps onto active KRAS and shuts down its growth signal. This approach has proven effective in a trial of 500 patients with metastatic pancreatic cancer who had already received prior treatment.
Patients on daraxonrasib lived a median of 13.2 months, compared to 6.7 months on standard chemotherapy, representing a 60% reduction in the risk of death.
The Trial Results
The trial results, published in the New England Journal of Medicine, show that daraxonrasib has the potential to be a significant advance in pancreatic cancer treatment. The side effects of the drug, which include a skin rash in most patients, mouth sores, diarrhea, and nausea, were found to be manageable, with patients less likely to stop treatment than with chemotherapy.
Additionally, patients on daraxonrasib reported a better quality of life. Experts describe daraxonrasib as potentially the most significant advance in pancreatic cancer treatment in a generation. However, they also note that the drug still awaits regulatory approval.
The developer of the drug, Revolution Medicines, has released the results of the trial, which provide a glimmer of hope for patients with this devastating disease.
A key aspect of daraxonrasib is its ability to target multiple RAS mutations at once, making it harder for the cancer to develop resistance. The fact that daraxonrasib has shown such promise in a Phase 3 trial is a major breakthrough, and one that could potentially lead to new treatment options for patients with advanced pancreatic cancer.
As the medical community awaits regulatory approval, patients with pancreatic cancer can take heart from the progress being made in the development of new treatments.
While there is still much work to be done, the results of the daraxonrasib trial offer a beacon of hope in the fight against this devastating disease. Patients with concerns should consult their doctor.
